cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Shattuck Labs Inc
7 own
9 watching
Current Price
$1.4
$0.14
(11.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
223M
52-Week High
52-Week High
11.76000
52-Week Low
52-Week Low
1.07000
Average Volume
Average Volume
2.09M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization223M
icon52-Week High11.76000
icon52-Week Low1.07000
iconAverage Volume2.09M
iconDividend Yield--
iconP/E Ratio--
What does the Shattuck Labs Inc do?
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Read More
How much money does Shattuck Labs Inc make?
News & Events about Shattuck Labs Inc.
Benzinga
1 year ago
Latest Ratings for STTK DateFirmActionFromTo Apr 2021BerenbergInitiates Coverage OnBuy Jan 2021Evercore ISI GroupInitiates Coverage OnOutperform Nov 2020Cowen & Co.Initiates Coverage OnOutperform View More Analyst Ratings for STTK View the Latest Analyst Ratings read more...
Globe Newswire
1 year ago
CD20-targetedGADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease AUSTIN, TX and DURHAM, NC, March 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a ...
Globe Newswire
1 year ago
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune ...
Benzinga
1 year ago
Shattuck Labs (NASDAQ:STTK) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Shattuck Labs will report an earnings per share (EPS) of $-0.67. read more...
Business Wire
2years ago
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on behalf of long-term stockholders following a class action complaint that was filed against Shattuck on February 11, 2022 with a...
Frequently Asked Questions
Frequently Asked Questions
What is Shattuck Labs Inc share price today?
plus_minus_icon
Can Indians buy Shattuck Labs Inc shares?
plus_minus_icon
How can I buy Shattuck Labs Inc shares from India?
plus_minus_icon
Can Fractional shares of Shattuck Labs Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Shattuck Labs Inc stocks?
plus_minus_icon
What is today’s traded volume of Shattuck Labs Inc?
plus_minus_icon
What is today’s market capitalisation of Shattuck Labs Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Shattuck Labs Inc?
plus_minus_icon
What percentage is Shattuck Labs Inc down from its 52-Week High?
plus_minus_icon
What percentage is Shattuck Labs Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.4
$0.14
(11.11%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$63.10
$-1.67 (-2.58 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$5.11
$-0.14 (-2.76 %)
GENERATION BIO CO
GENERATION BIO CO
$2.40
$0.08 (3.45 %)
ADC Therapeutics SA
ADC Therapeutics SA
$2.87
$-0.20 (-6.51 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$63.10
$-1.67 (-2.58 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$5.11
$-0.14 (-2.76 %)
GENERATION BIO CO
GENERATION BIO CO
$2.40
$0.08 (3.45 %)
ADC Therapeutics SA
ADC Therapeutics SA
$2.87
$-0.20 (-6.51 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00